ARCHIVES

Survival Benefit For Vinorelbine-Cisplatin In NSCLC Patient, Phase III Trial Finds

This article is from The Cancer Letter archive.

Vol. 28 No. 8 | August 26, 2005

Download PDF Visit The Full Archive

Related Articles

NCI Spent $381.2 Million On PR From 2006 to 2012, Vastly Outspending Other NIH, FDA Units

March 1, 2013

In Brief: CFO Dwain Morris to Leave MD Anderson Cancer Center

May 2, 2014

Panel Debates Whether DCIS Needs A New Name

September 25, 2009

Obituary: Connie Curran, 67, C-Change Executive Director

November 21, 2014

In Brief: ASTRO Officers Named; AACR Fellowships Available; NRC Won’t Revoke NIH License

November 10, 1995

T-Cell Vaccines Cut Time To Protective Immunity

November 25, 2005